TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32852460
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy (0.3 mg conjugated equine oestrogens plus 1.5 mg medroxyprogesterone acetate)
Study: 32620163
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle)
Study: 32620163
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Pegylated liposomal doxorubicin (PLD) + cyclophosphamide + ipilimumab (1 mg intravenously every 6th week) + nivolumab (240 mg intravenously every 2nd week)
Study: 35837209
Drug: LiSi surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LiSi surface treatment
Study: 32272659
Drug: OM3-sn-1(3)-monoacylglycerol (OM3-MAG)
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-sn-1(3)-monoacylglycerol (OM3-MAG) at 2.9 g/day
Study: 32272659
Drug: OM3-ethyl ester
Normalized name: creatine ethyl ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-ethyl ester at 3.1 g/day
Study: 32272659
Drug: OM3-free fatty
Normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-free fatty acids (OM3-FFA) at 3.2 g/day
Study: 32272659
Drug: OM3-triacylglycerols (OM3-TAG)
Normalized name: ALLERGENIC EXTRACT, TAG ALDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-triacylglycerols (OM3-TAG) at 1.2 g/day
Study: 32272659
Drug: OM3 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3 at 1.0 g/day
Study: 35543647
Drug: Psychologically informed
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychologically informed physical therapy (PIPT)
Study: 34160125
Drug: In-office gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office gel with bioactive nanoparticles (n-Bm)
Study: 34160125
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - only in-office gel
Study: 37605110
Drug: Multimodal machine‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal machine‐based exercise training programme (twice weekly for 45-60 min over six months)
Study: 35197248
Drug: Regular preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular preparation for the running event (Control)
Study: 32386747
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg GMZ2-alum
Study: 32386747
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (rabies vaccine)
Study: 35427495
Drug: 4-month anti-TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month anti-TNF therapy and surgical closure
Study: 34648734
Drug: Intramuscular long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular long-acting cabotegravir (600 mg) and rilpivirine (900 mg) every 8 weeks
Study: 34648734
Drug: Intramuscular long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular long-acting cabotegravir (400 mg) and rilpivirine (600 mg) every 4 weeks
Study: 34648734
Drug: Injection site
Normalized name: Dual Injection Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection site reactions in every 8-week group
Study: 34648734
Drug: Injection site
Normalized name: Dual Injection Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection site reactions in every 4-week group
Study: 32819728
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intra-articular tranexamic acid (TXA)
Study: 32819728
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intra-articular tranexamic acid (TXA)
Study: 35043484
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg plus doxazosin 2 mg once daily
Study: 35043484
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg plus doxazosin 2 mg
Study: 36408831
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy Driving Intervention (OT‐DI)
Study: 35346148
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program based on the Health Belief Model (HBM) with five consecutive weekly sessions
Study: 32544221
Drug: Whole tablet
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole tablet elbasvir/grazoprevir
Study: 35933730
Drug: CSL112 (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (2, 4, or 6 g)
Study: 35555129
Drug: Home-based leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based leg heat therapy (HT), n=15
Study: 35555129
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (CON), n=14
Study: 33504865
Drug: Community health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community health workers (CHWs) treatment for SAM
Study: 33728436
Drug: Weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly carboplatin plus nab-paclitaxel
Study: 33728436
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose carboplatin
Study: 36260986
Drug: Worksite-based intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worksite-based intensive lifestyle therapy
Study: 32761638
Drug: 12-week daily
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week daily reminders
Study: 33341312
Drug: Calcitriol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (1 mcg/day)
Study: 32792167
Drug: Therapeutic agents
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic agents for human therapy in patients with COVID-19
Study: 32792167
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of available drugs and prospective therapies
Study: 34181276
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2)
Study: 32776831
Drug: Pharmaceutical workers
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical workers
Study: 32776831
Drug: Non-pharmaceutical subjects
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmaceutical subjects
Study: 39258531
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous alteplase
Study: 39258531
Drug: Standard-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intravenous alteplase
Study: 34988183
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (ONS) 300 mL/day for 4 weeks
Study: 33278332
Drug: M‐NMB, sugammadex
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐NMB, sugammadex 2 mg/kg ABW
Study: 33278332
Drug: M‐NMB, sugammadex
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐NMB, sugammadex 2 mg/kg IBW
Study: 33278332
Drug: M‐NMB, neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐NMB, neostigmine 5 mg + glycopyrrolate 1 mg
Study: 33278332
Drug: D‐NMB, sugammadex
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐NMB, sugammadex 4 mg/kg ABW
Study: 33278332
Drug: D‐NMB, sugammadex
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐NMB, sugammadex 4 mg/kg IBW
Study: 35938345
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia (IV)
Study: 33512910
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (1000 mg) and targeted therapy
Study: 33512910
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy alone
Study: 32580978
Drug: Laparoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic therapy plus propranolol
Study: 32580978
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy plus propranolol
Study: 37946314
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) treatment
Study: 34983775
Drug: DX1 (dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX1 (dexamethasone 24 mg + placebo)
Study: 34983775
Drug: DX2 (dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX2 (dexamethasone 24 mg + dexamethasone 24 mg)
Study: 34983775
Drug: Dexamethasone (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (one dose)
Study: 34983775
Drug: Dexamethasone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (two doses)
Study: 34637494
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 supplementation (10 mg/d)
Study: 34615722
Drug: Anthracycline adjuvant
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline adjuvant chemotherapy in basal breast cancer patients
Study: 32998098
Drug: Salt stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt stress treatment (low, medium, high)
Study: 33126334
Drug: Motion Style
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motion Style Acupuncture Treatment (MSAT)
Study: 33126334
Drug: Acupuncture Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture Treatment
Study: 34289338
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 or 2.0 mg (all treatment arms pooled)
Study: 34335043
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy combined with static magnetic field (PBMT-sMF)
Study: 35266003
Drug: Haemodynamic-guided management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemodynamic-guided management (treatment)
Study: 35392354
Drug: Intravenous Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ketamine (0.5 mg/kg)
Study: 35392354
Drug: Intrathecal Meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal Meperidine (0.2 mg/kg)
Study: 35392354
Drug: Intravenous Normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Normal Saline (placebo)
Study: 35364722
Drug: 1540nm non-ablative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1540nm non-ablative fractional laser (NAFL) combined with silicones treatment
Study: 35364722
Drug: Silicones alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicones alone treatment
Study: 36176051
Drug: Vutiglabridin (30-720
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vutiglabridin (30-720 mg single dose)
Study: 36176051
Drug: Vutiglabridin (240-480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vutiglabridin (240-480 mg once daily for 14 days)
Study: 36176051
Drug: Vutiglabridin (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vutiglabridin (240 mg single dose) with food effect evaluation
Study: 36176051
Drug: Vutiglabridin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vutiglabridin (multiple doses)
Study: 34474622
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy (ESWT) applied to paraspinal muscles
Study: 34474622
Drug: Neuro‐Developmental Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuro‐Developmental Treatment (NDT) programs
Study: 36072410
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) combined with 50 mg diclofenac sodium (DS) sustained-release capsules once a day, treated three times in 7 days.
Study: 36072410
Drug: Low-dose diclofenac
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose diclofenac sodium (50 mg DS sustained-release capsules once a day).
Study: 36072410
Drug: Conventional-dose diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose diclofenac sodium (100 mg DS sustained-release capsules once a day).
Study: 32282572
Drug: Trunk stabilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trunk stabilization training robot (3DBT‐33) in addition to conventional physical therapy (30 min)
Study: 36368938
Drug: Individualised medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised medicine management plan (MMP) plus Discharge Medical Service (DMS)
Study: 33470681
Drug: Topical ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular hypertonic saline
Study: 35354614
Drug: DGAT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DGAT2 inhibitor (PF‐06865571, ervogastat) 25-300 mg BID or 150-300 mg once a day
Study: 35354614
Drug: DGAT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DGAT2 inhibitor (PF‐06865571, ervogastat) 150-300 mg BID + ACC inhibitor (PF‐05221304, clesacostat) 5-10 mg BID
Study: 34107792
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical silicone gel and pressure garment
Study: 32360852
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with a diode laser (670 nm, 150 mW, 1.1 W/cm2) and methylene blue photosensitizer (0.005% concentration) applied once at baseline.
Study: 32360852
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with adjunctive mechanical debridement.
Study: 32363592
Drug: Varenicline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (up to 2 mg/d)
Study: 33499916
Drug: Normobaric oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygenation (NBO) - high-flow oxygen (8 L/min, 1 hour each time for 6 cycles daily) and low-flow oxygen (2 L/min) for a total of 7 days.
Study: 33499916
Drug: Low-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow oxygen (2 L/min) by mask for 7 consecutive days (Control group).
Study: 33499916
Drug: Low-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow oxygen (2 L/min) (Control group)
Study: 32857616
Drug: 2,000 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 IU/day oral vitamin D supplementation for 4 weeks
Study: 35134631
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil (taken three times daily)
Study: 34744686
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical activity intervention (twice a week for 45 min, lasting 16 weeks)
Study: 32889793
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health knowledge assessment
Study: 32889793
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health attitude assessment
Study: 32889793
Drug: Knowledge about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge about diet and oral hygiene
Study: 32889793
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health behaviors and practices
Study: 32706400
Drug: L‐shaped miniplate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐shaped miniplate osteosynthesis (P2)
Study: 35294738
Drug: Curcuwin Ultra+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuwin Ultra+ (CU+) 250 mg
Study: 35294738
Drug: Curcuwin Ultra+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuwin Ultra+ (CU+) 500 mg
Study: 35294738
Drug: TUR1800 1900
Approvals — FDA: no, EMA: no, PMDA: no
Description: TUR1800 1900 mg
Study: 34794330
Drug: Calorie-restricted diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie-restricted diet enriched with 39-60 g/d of mixed nuts (CRDEN) for 8 weeks
Study: 32429465
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (CT + B)
Study: 34959823
Drug: Inositol-stabilized arginine
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol-stabilized arginine silicate (ASI) (1.5 g ASI + 12 g dextrose)
Study: 34319940
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 g dextrose)
Study: 32370802
Drug: 0.6 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/day folic acid
Study: 32370802
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day (6S)-5-methyltetrahydrofolic acid
Study: 35831241
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma therapy (3 application sessions at 15-day intervals)
Study: 35636621
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation (64 Gy vs 70 Gy)
Study: 33626969
Drug: JNJ‐55920839 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐55920839 (10 mg/kg IV doses every 2 weeks)
Study: 32162813
Drug: Oral NEPA
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral NEPA
Study: 32660282
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg every-2-weeks
Study: 32997575
Drug: Dacarbazine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine 1,000 mg/m2 every 3 weeks
Study: 32406770
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (100% equivalent dose with conventional protocol)
Study: 32406770
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (80% equivalent dose)
Study: 32406770
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C (64% equivalent dose)
Study: 33593768
Drug: Intensive praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive praziquantel (PZQ) treatment: three doses, each 2 weeks apart before BCG immunisation, followed by a dose at week 8 and quarterly thereafter.
Study: 33593768
Drug: Standard praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard praziquantel (PZQ) treatment: doses at week 8 and 52.
Study: 33593768
Drug: Intensive praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive praziquantel (PZQ) treatment
Study: 33593768
Drug: Standard praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard praziquantel (PZQ) treatment
Study: 36125447
Drug: TRM (δ-tocotrienol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRM (δ-tocotrienol 250 mg; resveratrol 150 mg)
Study: 36125447
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose 400 mg)
Study: 34410414
Drug: Standard antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet treatment
Study: 36068181
Drug: Behavioural intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioural intervention to increase physical activity in daily living (PADL)
Study: 32960643
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (21 g over a week, 7 g per day on Monday, Wednesday, and Friday)
Study: 33012654
Drug: Migalastat 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migalastat 150 mg every other day (QOD)
Study: 32539786
Drug: Oral non-absorbable
Normalized name: Tavist Non-Sedating Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral non-absorbable antibiotic prophylaxis (OAP) with tobramycin and colistin for three days preoperatively
Study: 35723850
Drug: Thymus kotschyanus
Normalized name: THYMUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymus kotschyanus extract (0.5 g/day)
Study: 35553446
Drug: TRF with
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRF with whey protein supplementation (25 g/d)
Study: 34061178
Drug: Left-sided KRAS
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left-sided KRAS wild-type tumors receiving anti-EGFR treatment
Study: 35482567
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dexmedetomidine (0.04 mg/kg, IM) + midazolam (3 mg/kg, IM)
Study: 35482567
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose dexmedetomidine (0.01 mg/kg, IM) + midazolam (3 mg/kg, IM)
Study: 32657946
Drug: Reltecimod (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reltecimod (0.5 mg/kg)
Study: 36496349
Drug: DWP16001 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 2 mg with gemigliptin (50 mg once-daily) and metformin (1000 mg twice-daily)
Study: 36496349
Drug: DWP16001 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 2 mg without gemigliptin and metformin
Study: 32618438
Drug: Marketed 150
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed 150 mg peficitinib tablet under fasted conditions
Study: 32618438
Drug: Marketed 150
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed 150 mg peficitinib tablet under fed conditions